Vor Biopharma (VOR) Equity Ratio (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Equity Ratio data on file, last reported at 0.3 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.3, down 149.11% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.3 (down 149.11% YoY), and the FY2025 annual result was 0.35, up 47.67% from the prior year.
• Equity Ratio improved to 0.3 in Q1 2026 per VOR's latest filing, from 0.35 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.84 in Q4 2022 and troughed at 12.63 in Q3 2025.
• A 5-year average of 0.72 and a median of 0.74 in 2024 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 47.67% in 2025 and fell as far as 2107.69% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.84 in 2022, then slipped by 9.12% to 0.76 in 2023, then tumbled by 188.92% to 0.68 in 2024, then jumped by 47.67% to 0.35 in 2025, then climbed by 16.15% to 0.3 in 2026.
• Business Quant data shows VOR's Equity Ratio at 0.3 in Q1 2026, 0.35 in Q4 2025, and 12.63 in Q3 2025.